Clinical Trial Results: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of pegylated IL-10 (pegilodecakin) in adults with advanced solid tumors; results from a first-in-human trial assessing safety and preliminary acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Carcinoma
• Melanoma
• Non-small Cell Lung Carcinoma
• Ovarian Cancer
• Pancreatic Carcinoma
• Prostate Cancer
• Renal Cell Carcinoma
• Solid Tumors

Drugs mentioned

• Pegilodecakin (LY3500518) (pegilodecakin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Melanoma, Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2026-07-09